Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. […]
